ORLANDO — In this video from the American Academy of Ophthalmology meeting, Michael W. Stewart, MD, discusses 3-year data from the GALE study on geographic atrophy treatment with pegcetacoplan.
Stewart said that the study of Syfovre (pegcetacoplan injection, Apellis Pharmaceuticals) found functional signals in microperimetry in a post hoc analysis, noting that it was the first analysis to find a functional difference between treated and untreated patients.
“It still hasn’t necessarily convinced me that the drugs are worth using, but at least it’s a step in a positive direction,” Stewart,